Although there are contrasting evidence with regards to BCL2 and BCL6 rearrangement prognostic impact 50, consensus exist that C-MYC rearrangement is the worse prognostic marker for DLBCL patients treated with either standard CHOP or R-CHOP5. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.